Several other GLP-1 RAs have been approved to date for subcutaneous (s.c.) use to treat T2DM, including liraglutide in 2009 (Europe) and 2010 (USA), exenatide ER in 2012, lixisenatide in 2013 (Europe) and 2016 (USA), dulaglutide in 2014, albiglutide in 2014 (Europe and USA), and semaglutide in 2017 (USA) and 2019 (Europe)
Easy to use Convenient dosage, simple to take
Fecal immunochemical test
You avoid the intense hunger that GHRP-6 triggers
These medications regulate appetite and slow digestion, leading to reduced calorie intake, fat loss, and better metabolic function
Efficacy of semaglutide in a subcutaneous and an oral formulation, Frontiers in Endocrinology (2021) Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts, Diabetes, Obesity , & Metabolism (2024) Effectiveness of oral versus injectable semaglutide in adults with Type 2 diabetes: Results from a retrospective observational study in Croatia, Diabetology (2024) Drug absorption, Merck Manual Rybelsus label, U.S
